Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005968 · ClinicalTrials.gov registry record · Phase 2
Irofulven in Treating Patients With Stage IV Melanoma
A Phase 2 study of Melanoma (Skin), sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Study locations
NCT00005968 is a Phase 2 study of Melanoma (Skin) that has completed, run by University of Colorado, Denver. The trial reports 5 study locations across 4 states.
The verdict
NCT00005968, a Phase 2 study of Melanoma (Skin), has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who have stage IV melanoma.
Conditions Studied
Interventions
- DRUG irofulven
Study Locations (5)
Colorado
- Veterans Affairs Medical Center - Denver - Denver
- University of Colorado Cancer Center - Denver
California
- John Wayne Cancer Institute - Santa Monica
Illinois
- Lutheran General Hospital - Park Ridge
Missouri
- Ellis Fischel Cancer Center - Columbia - Columbia
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-11 |
| Est. Completion | 2002-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005968
The ClinicalTrials.gov registry entry for NCT00005968 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 1 intervention - of which irofulven is the first listed.
NCT00005968 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Colorado, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00005968 about?
NCT00005968 is a clinical study titled "Irofulven in Treating Patients With Stage IV Melanoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who have stage IV melanoma.
What is the current status of trial NCT00005968?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-11. Estimated completion is 2002-12.
What conditions does trial NCT00005968 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT00005968?
The interventions under investigation include: irofulven (DRUG).
Who is sponsoring clinical trial NCT00005968?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005968 being conducted?
This trial has 5 study locations across California, Colorado, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
-
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
RECRUITING · Phase 2
-
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
COMPLETED · Phase 2
-
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
COMPLETED · Phase 2
-
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.